Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 10/2007

01-10-2007 | Article

GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77

Authors: M. Desai, C. A. Cull, V. A. Horton, M. R. Christie, E. Bonifacio, V. Lampasona, P. J. Bingley, J. C. Levy, I. R. Mackay, P. Zimmet, R. R. Holman, A. Clark

Published in: Diabetologia | Issue 10/2007

Login to get access

Abstract

Aims/hypothesis

Latent autoimmune diabetes in adults (LADA) is a slowly progressive form of autoimmune diabetes, with autoantibodies to islet proteins developing in older patients who have no immediate requirement for insulin therapy. Markers of its clinical course are uncharacterised. The aim of this study was to determine whether persistence of, or changes in, GAD65 autoantibodies (GADAs) in the LADA patients who participated in the United Kingdom Prospective Diabetes Study (UKPDS) were associated with disease progression or insulin requirement.

Methods

GADA levels and their relative epitope reactivities to N-terminal, middle and C-terminal regions of human GAD65 were determined in 242 UKPDS patients who were GADA-positive at diagnosis; samples taken after 0.5, 3 and 6 years of follow-up were tested using a radiobinding assay. Comparisons were made of GADA status with clinical details and disease progression assessed by the requirement for intensified glucose-lowering therapy.

Results

GADA levels fluctuated between 0.5 and 6 years but persisted in 225 of 242 patients. No association of GADA levels with disease progression or insulin requirement was observed. Antibody reactivity was directed to C-terminal and middle epitopes of GAD65 in >70% patients, and the N-terminal in <9%. There were no changes in epitope reactivity pattern over the 6 year follow-up period, nor any association between epitope reactivity and insulin requirement.

Conclusions/interpretation

GADAs persist for 6 years after diagnosis of LADA, but levels and reactivity to different GAD65 epitopes are not associated with disease progression.
Appendix
Available only for authorised users
Literature
1.
Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef
2.
Gottsater A, Ahmed M, Lilja B, Fernlund P, Sundkvist G (1996) Islet cell antibodies at diagnosis, but not leanness, relate to a better cardiovascular risk factor profile 5 years after diagnosis of NIDDM. Diabetes Care 19:60–63PubMedCrossRef
3.
Davis TM, Wright AD, Mehta ZM et al (2005) Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 48:695–702PubMedCrossRef
4.
Horton V, Stratton I, Bottazzo GF et al (1999) Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group. Diabetologia 42:608–616PubMedCrossRef
5.
Desai M, Zeggini E, Horton VA et al (2007) An association analysis of the HLA gene region in latent autoimmune diabetes in adults. Diabetologia 50:68–73PubMedCrossRef
6.
Sabbah E, Savola K, Kulmala P et al (1999) Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The Childhood Diabetes In Finland Study Group. J Clin Endocrinol Metab 84:1534–1539PubMedCrossRef
7.
Turner R, Stratton I, Horton V et al (1997) UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 350:1288–1293PubMedCrossRef
8.
UKPDS Group (1991) UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 34:877–890CrossRef
9.
Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005–2012PubMedCrossRef
10.
Bonifacio E, Lampasona V, Bernasconi L, Ziegler AG (2000) Maturation of the humoral autoimmune response to epitopes of GAD in preclinical childhood type 1 diabetes. Diabetes 49:202–208PubMedCrossRef
11.
Hatfield EC, Hawkes CJ, Payton MA, Christie MR (1997) Cross reactivity between IA-2 and phogrin/IA-2beta in binding of autoantibodies in IDDM. Diabetologia 40:1327–1333PubMedCrossRef
12.
Piquer S, Belloni C, Lampasona V et al (2005) Humoral autoimmune responses to glutamic acid decarboxylase have similar target epitopes and subclass that show titer-dependent disease association. Clin Immunol 117:31–35PubMedCrossRef
13.
(UKPDS). UPDS (1994) XI: Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11:534–544
14.
Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191–2192PubMedCrossRef
15.
Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef
16.
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef
17.
Borg H, Gottsater A, Fernlund P, Sundkvist G (2002) A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 51:1754–1762PubMedCrossRef
18.
Hampe CS, Hammerle LP, Bekris L et al (2002) Stable GAD65 autoantibody epitope patterns in type 1 diabetes children five years after onset. J Autoimmun 18:49–53PubMedCrossRef
19.
Christie MR, Daneman D, Champagne P, Delovitch TL (1990) Persistence of serum antibodies to 64,000-Mr islet cell protein after onset of type I diabetes. Diabetes 39:653–656PubMedCrossRef
20.
Pipeleers D, Ling Z (1992) Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev 8:209–227PubMedCrossRef
21.
Shimada A, Imazu Y, Morinaga S et al (1999) T-cell insulitis found in anti-GAD65+ diabetes with residual beta-cell function. A case report. Diabetes Care 22:615–617PubMedCrossRef
22.
Bottazzo GF, Bosi E, Cull CA et al (2005) IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 48:703–708PubMedCrossRef
23.
24.
Batstra MR, Pina M, Quan J et al (1997) Fluctuations in GAD65 antibodies after clinical diagnosis of IDDM in young children. Diabetes Care 20:642–644PubMedCrossRef
25.
Savola K, Sabbah E, Kulmala P et al (1998) Autoantibodies associated with Type I diabetes mellitus persist after diagnosis in children. Diabetologia 41:1293–1297PubMedCrossRef
26.
Castleden HA, Shields B, Bingley PJ et al (2006) GAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes. Diabet Med 23:834–838PubMedCrossRef
27.
Hosszufalusi N, Vatay A, Rajczy K et al (2003) Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression. Diabetes Care 26:452–457PubMedCrossRef
28.
Tuomi T, Carlsson A, Li H et al (1999) Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150–157PubMedCrossRef
29.
Lohmann T, Kellner K, Verlohren HJ et al (2001) Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia 44:1005–1010PubMedCrossRef
30.
Davis TM, Zimmet P, Davis WA et al (2000) Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabet Med 17:667–674PubMedCrossRef
31.
Padoa CJ, Banga JP, Madec AM et al (2003) Recombinant Fabs of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs. Diabetes 52:2689–2695PubMedCrossRef
32.
Falorni A, Gambelunghe G, Forini F et al (2000) Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus. J Clin Endocrinol Metab 85:309–316PubMedCrossRef
33.
Kobayashi T, Tanaka S, Okubo M et al (2003) Unique epitopes of glutamic acid decarboxylase autoantibodies in slowly progressive type 1 diabetes. J Clin Endocrinol Metab 88:4768–4775PubMedCrossRef
34.
Desai M, Clark A (2006) Comment on Gale EAM (2005) Latent Autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 49:2222PubMedCrossRef
35.
Desai M, Zeggini E, Horton VA et al (2006) The variable number of tandem repeats upstream of the insulin gene is a susceptibility locus for latent autoimmune diabetes in adults. Diabetes 55:1890–1894PubMedCrossRef
36.
UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837–853CrossRef
Metadata
Title
GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77
Authors
M. Desai
C. A. Cull
V. A. Horton
M. R. Christie
E. Bonifacio
V. Lampasona
P. J. Bingley
J. C. Levy
I. R. Mackay
P. Zimmet
R. R. Holman
A. Clark
Publication date
01-10-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0745-6

Other articles of this Issue 10/2007

Diabetologia 10/2007 Go to the issue

Article

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus

Research Letter

Regulation of retinol binding protein 4 production in primary human adipocytes by adiponectin, troglitazone and TNF-α

Article

GLUT2 protein at the rat proximal tubule brush border membrane correlates with protein kinase C (PKC)-βl and plasma glucose concentration

Erratum

Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes

Article

The influence of dietary intake and meal pattern on blood glucose control in children and adolescents using intensive insulin treatment

Erratum

The BioBreeding rat diabetes model is infected with Ljungan virus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits